SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

Search

Pharma Mar SA

Open

75.25 -5.76

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

74.5

Max

79.95

Schlüsselkennzahlen

By Trading Economics

Einkommen

5.7M

9.5M

Verkäufe

2.7M

48M

KGV

Branchendurchschnitt

1,996.25

63.778

EPS

1.063

Dividendenrendite

0.81

Gewinnspanne

19.737

Angestellte

500

EBITDA

8.2M

15M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+33.91% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.81%

2.39%

Nächstes Ergebnis

22. Apr. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.4B

Vorheriger Eröffnungskurs

81.01

Vorheriger Schlusskurs

75.25

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Pharma Mar SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Apr. 2025, 23:04 UTC

Top News

JPMorgan Raises Risk of U.S., Global Recession to 60%

3. Apr. 2025, 22:40 UTC

Wichtige Markttreiber

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3. Apr. 2025, 22:18 UTC

Akquisitionen, Fusionen, Übernahmen

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3. Apr. 2025, 18:51 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3. Apr. 2025, 23:43 UTC

Market Talk

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3. Apr. 2025, 23:41 UTC

Market Talk

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3. Apr. 2025, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3. Apr. 2025, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3. Apr. 2025, 21:43 UTC

Top News
Ergebnisse

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3. Apr. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3. Apr. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. Apr. 2025, 20:43 UTC

Market Talk

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3. Apr. 2025, 20:34 UTC

Top News

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3. Apr. 2025, 20:23 UTC

Top News

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3. Apr. 2025, 20:15 UTC

Akquisitionen, Fusionen, Übernahmen

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3. Apr. 2025, 19:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. Apr. 2025, 19:55 UTC

Market Talk

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3. Apr. 2025, 19:21 UTC

Market Talk

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3. Apr. 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3. Apr. 2025, 18:45 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3. Apr. 2025, 18:45 UTC

Market Talk

Gold Drops In Tariff Fallout -- Market Talk

3. Apr. 2025, 18:39 UTC

Market Talk

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3. Apr. 2025, 18:38 UTC

Top News

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3. Apr. 2025, 18:30 UTC

Top News

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3. Apr. 2025, 18:20 UTC

Market Talk

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3. Apr. 2025, 18:18 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3. Apr. 2025, 18:17 UTC

Market Talk

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3. Apr. 2025, 18:04 UTC

Market Talk

US Sees More Job Openings in Construction, Transportation -- Market Talk

3. Apr. 2025, 17:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Pharma Mar SA Prognose

Kursziel

By TipRanks

33.91% Vorteil

12-Monats-Prognose

Durchschnitt 107.998 EUR  33.91%

Hoch 108 EUR

Tief 108 EUR

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pharma Mar SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

1

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

78.6 / 90.2Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Very Strong Bearish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.